<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601106</url>
  </required_header>
  <id_info>
    <org_study_id>NL37190.018.11</org_study_id>
    <nct_id>NCT01601106</nct_id>
  </id_info>
  <brief_title>Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease</brief_title>
  <acronym>SILENCE</acronym>
  <official_title>A Phase I/II, Single-Center, Randomized, Placebo-Controlled Study Evaluating the Therapeutic Efficacy of Intravenously Injected PEG-liposomal Prednisolone Sodium Phosphate (NanocortÂ®) in Subjects With Severe Inflamed Carotid or Aortic Atherosclerosis Plaques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <brief_summary>
    <textblock>
      Cardiovascular disease(CVD) is the leading cause of morbidity and mortality in developed&#xD;
      nations. CVD is primarily caused by atherosclerosis, a systemic disease characterized by&#xD;
      lipid deposition in the subendothelial space with a concomitant, low-grade inflammatory&#xD;
      reaction.(Fuster, Moreno et al. 2005) To date, most therapeutic interventions aimed at&#xD;
      lowering CVD have thus far focused on modulating lipid levels, either lowering LDLc or&#xD;
      increasing HDLc levels. Yet, since the introduction of statins 20 years ago, there have been&#xD;
      few breakthroughs in the treatment of this disease. A promising strategy to reduce CVD is to&#xD;
      directly target inflammation at the level of the vessel wall.(van Leuven, van Wijk et al.;&#xD;
      Libby 2002) A potential drawback of anti-inflammatory strategies pertains to the thin line&#xD;
      between inhibiting 'inappropriate' inflammation versus inducing immuno-suppression.&#xD;
      Therefore, continuous low dosed anti-inflammatory drugs have great potential as novel&#xD;
      treatment strategies. In the present project, the investigators propose to inject liposomal&#xD;
      glucocorticoids intravenously in patients with an increased risk of atherosclerotic disease&#xD;
      aiming to reduce vessel wall inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18Fludeoxyglucose Positron emission computed tomography scan (18FDG PET-CT scan)</measure>
    <time_frame>Day 8-13</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Liposomal prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal prednisolone</intervention_name>
    <description>Two weekly dosages with 150 mg.</description>
    <arm_group_label>Liposomal prednisolone</arm_group_label>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Population with target to background ratio of 2.2 of the aorta or carotid artery on&#xD;
             PET-CT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current medical history of auto-immune disease/vasculitis, active inflammatory&#xD;
             diseases, Recent (&lt;1 month prior to screening) or ongoing serious infection requiring&#xD;
             IV antibiotic therapy.&#xD;
&#xD;
          -  Recent or current treatment with medications that may have a significant effect on&#xD;
             plaque inflammation as measured by plaque TBR, including but not limited to:&#xD;
&#xD;
               -  Steroids for at least 6 weeks prior to baseline measurement and during study&#xD;
                  (with the exception of inhaled acute use steroids).&#xD;
&#xD;
               -  Biological based medicines (anti-TNF (ex. Infliximab), anti-IL-6 therapy (ex.&#xD;
                  Tocilizumab) or anti-IL-1 (ex. anakinra)) within 8 weeks before the baseline&#xD;
                  visit and during the study&#xD;
&#xD;
               -  No other disease modifying antirheumatic drugs (DMRADS) within 6 weeks of&#xD;
                  baseline and during study (such as cyclosporine, azatioprine, etc.)&#xD;
&#xD;
          -  Known systemic disorders such as hepatic, renal, hematologic, and malignant diseases&#xD;
             or any clinically significant medical condition that could interfere with the conduct&#xD;
             of the study.&#xD;
&#xD;
          -  Changes in dose or frequency of doses at least 6 weeks prior to baseline measurement&#xD;
             (unstable dosing) in angiotensin-converting enzyme (ACE) inhibitors (ACE-I) or&#xD;
             angiotensin-receptor blockers (ARBs), non-statin lipid-modifying therapy,&#xD;
             thiazolidinediones, inhaled steroids, or leukotriene modifying agents, nonsteroidal&#xD;
             anti-inflammatory drugs (NSAIDS), and cyclo-oxygenase-2 inhibitors (COXIBs)&#xD;
&#xD;
          -  Standard contra-indications to MRI, 18FDG PET, and CT based on physicians experience&#xD;
             and current practices&#xD;
&#xD;
          -  Current medical history of poorly controlled diabetes defined as hemoglobin A1c&#xD;
             (HbA1c) &gt;7.5%.&#xD;
&#xD;
          -  Current medical history of drug or alcohol abuse within 12 months prior to screening.&#xD;
&#xD;
          -  History of anaphylaxis, anaphylactoid (resembling anaphylaxis) reactions, or severe&#xD;
             allergic responses.&#xD;
&#xD;
          -  Inability or unwillingness to comply with the protocol requirements, or deemed by&#xD;
             investigator to be unfit for the study.&#xD;
&#xD;
          -  Subject has planned cardiac surgery, PCI or carotid stenting, or major non-cardiac&#xD;
             surgery during the course of the study period or for 14 days after the last treatment.&#xD;
&#xD;
          -  Use of any investigational drug in the 3 months prior to study drug administration.&#xD;
&#xD;
          -  Use of insulin or any oral anti-diabetic (except metformin) in the 30 days prior to&#xD;
             baseline measurements. Those subjects who are taking metformin may be included in the&#xD;
             study if they are on a stable dose for at least 4 weeks and have a HbA1c &lt;7.5%.&#xD;
&#xD;
          -  Any contraindications for corticosteroid infusions (for example, but not limited&#xD;
             current infections or vaccinations)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik S Stroes, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Malignancy Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik S. Stroes, MD PhD</last_name>
    <phone>+31205665978</phone>
    <email>e.s.stroes@amc.uva.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik S Stroes, MD PhD</last_name>
      <phone>+31205665978</phone>
      <email>e.s.stroes@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Erik S Stroes, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>E.S.stroes</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Atherosclerosis, inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

